JP3583128B2 - ワクチン製剤 - Google Patents

ワクチン製剤 Download PDF

Info

Publication number
JP3583128B2
JP3583128B2 JP51552994A JP51552994A JP3583128B2 JP 3583128 B2 JP3583128 B2 JP 3583128B2 JP 51552994 A JP51552994 A JP 51552994A JP 51552994 A JP51552994 A JP 51552994A JP 3583128 B2 JP3583128 B2 JP 3583128B2
Authority
JP
Japan
Prior art keywords
vaccine
immunogen
vaccine formulation
adjuvant
adsorbed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP51552994A
Other languages
English (en)
Japanese (ja)
Other versions
JPH08505152A (ja
Inventor
クーパー コックス，ジョン
エドワード スパークス，ロバート
クレイ ジェイコブス，アーウィン
サイモン メイスン，ノーバート
Original Assignee
シーエスエル、リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21701000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP3583128(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by シーエスエル、リミテッド filed Critical シーエスエル、リミテッド
Publication of JPH08505152A publication Critical patent/JPH08505152A/ja
Application granted granted Critical
Publication of JP3583128B2 publication Critical patent/JP3583128B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
JP51552994A 1993-01-08 1993-12-24 ワクチン製剤 Expired - Lifetime JP3583128B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US248593A 1993-01-08 1993-01-08
US08/002,485 1993-01-08
PCT/AU1993/000677 WO1994015636A1 (en) 1993-01-08 1993-12-24 Vaccine preparations

Publications (2)

Publication Number Publication Date
JPH08505152A JPH08505152A (ja) 1996-06-04
JP3583128B2 true JP3583128B2 (ja) 2004-10-27

Family

ID=21701000

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51552994A Expired - Lifetime JP3583128B2 (ja) 1993-01-08 1993-12-24 ワクチン製剤

Country Status (9)

Country Link
EP (1) EP0678035B9 (de)
JP (1) JP3583128B2 (de)
KR (1) KR100291357B1 (de)
AT (1) ATE218884T1 (de)
AU (1) AU667003B2 (de)
CA (1) CA2152949C (de)
DE (1) DE69332031T2 (de)
NZ (1) NZ259285A (de)
WO (1) WO1994015636A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM855194A0 (en) * 1994-10-04 1994-10-27 Csl Limited Controlled-release pharmaceutical preparations
US5958455A (en) * 1996-02-09 1999-09-28 Quadrant Holdings Cambridge Ltd Oral solid dosage forms, methods of making same and compositions thereof
EP1579851A3 (de) * 1997-08-29 2009-09-02 Corixa Corporation Schnellfreisetzende enkapsulierte bioaktive Wirkstoffe zur Induzierung oder Erhöhung einer immunantwort und Verwendung derselben
US6312731B1 (en) * 1997-08-29 2001-11-06 Southern Research Institute Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
ATE452651T1 (de) 1998-09-01 2010-01-15 Merrion Res Iii Ltd Orale impfstoff-zusammensetzung
US6498153B1 (en) 1998-12-31 2002-12-24 Akzo Nobel N.V. Extended release growth promoting two component composition
GB9906695D0 (en) * 1999-03-24 1999-05-19 Secr Defence Vaccine composition
ES2272447T3 (es) * 2000-03-22 2007-05-01 The Secretary Of State For Defence Composicion farmaceutica para aplicar en superficies mucosas.
IL153241A0 (en) * 2000-06-08 2003-07-06 Powderject Vaccines Inc Powder compositions
FR2814957B1 (fr) * 2000-10-06 2002-12-20 Aventis Pasteur Composition vaccinale et procede de stabilisation
FR2825276B1 (fr) * 2001-05-31 2004-11-26 Seppic Sa Adujvant d'immunite sous forme solide et vaccin le contenant
FR2873386B1 (fr) 2004-07-22 2011-01-14 Agence Francaise De Securite Sanitaire Des Aliments Afssa Composition vaccinale contre le rhodococcus equi
EP2068834A2 (de) * 2006-09-08 2009-06-17 Becton, Dickinson & Company Stabile pulverformulierungen aus alaun-adsorbierten impfstoffen
AU2008231072B2 (en) * 2007-03-22 2013-08-01 The Regents Of The University Of Colorado Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
PT2079456E (pt) 2007-04-04 2013-03-13 Sigmoid Pharma Ltd Composições farmacêuticas de ciclosporina
BRPI1012196B1 (pt) 2009-05-18 2021-11-30 Sublimity Therapeutics Limited Composição compreendendo gotas de óleo
GB2485327A (en) * 2009-08-12 2012-05-09 Sigmoid Pharma Ltd Immunomodulatory compositions comprising a polymer matrix and an oil phase
WO2012038801A1 (en) * 2010-09-21 2012-03-29 National Institute Of Immunology A spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
FR2977800B1 (fr) * 2011-07-13 2014-03-14 Sanofi Pasteur Composition vaccinale avec des nanoparticules d'hydroxyde d'aluminium
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
CN107106644B (zh) 2014-11-07 2022-04-15 卓越治疗有限公司 包含环孢菌素的组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH645270A5 (en) * 1979-10-11 1984-09-28 Schweiz Serum & Impfinst Vaccine against coli bacillosis of piglets and process for its preparation
HU188847B (en) * 1983-02-22 1986-05-28 Human Oltoanyagtermeloe Es Kutato Intezet,Hu Process for producing liophylized combined vaccines
JPS60193925A (ja) * 1984-03-13 1985-10-02 Chemo Sero Therapeut Res Inst 凍結乾燥製剤化ワクチン
AU620149B2 (en) * 1988-08-18 1992-02-13 Vaxine Pty Ltd Gamma inulin compositions
US5242686A (en) * 1990-11-07 1993-09-07 American Home Products Corporation Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same
CA2097830C (en) * 1990-12-04 2000-02-01 Stephen G. Newman Spray-dried antigenic products and method of preparation
CA2126685C (en) * 1992-10-26 2002-07-23 Bruno Gander Process for the production of microcapsules

Also Published As

Publication number Publication date
ATE218884T1 (de) 2002-06-15
EP0678035A4 (de) 1997-02-26
EP0678035A1 (de) 1995-10-25
DE69332031T2 (de) 2002-12-19
CA2152949A1 (en) 1994-07-21
NZ259285A (en) 1996-07-26
KR100291357B1 (ko) 2001-09-17
AU667003B2 (en) 1996-02-29
EP0678035B1 (de) 2002-06-12
EP0678035B9 (de) 2006-12-13
AU5805394A (en) 1994-08-15
DE69332031D1 (de) 2002-07-18
WO1994015636A1 (en) 1994-07-21
JPH08505152A (ja) 1996-06-04
KR960700070A (ko) 1996-01-19
CA2152949C (en) 2009-02-24

Similar Documents

Publication Publication Date Title
US5902565A (en) Spray dried vaccine preparation comprising aluminium adsorbed immunogens
JP3583128B2 (ja) ワクチン製剤
US6753015B2 (en) Microparticle compositions and methods for the manufacture thereof
JP5832485B2 (ja) 吸着したポリペプチド含有分子を有する微粒子
O'Hagan Microparticles and polymers for the mucosal delivery of vaccines
JP2739570B2 (ja) 単一注射ワクチン剤形
AU2001294898A1 (en) Microparticle compositions and methods for the manufacture thereof
Kissel et al. Injectable biodegradable microspheres for vaccine delivery
JP2001511148A (ja) 免疫応答を刺激するための吸着された抗原を有するマイクロパーティクルの使用
WO2005020964A1 (en) Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
US20020009466A1 (en) Oral vaccine compositions
JP4601823B2 (ja) 経口ワクチン組成物
CA2731995C (en) Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor
Howard et al. The development of controlled release vaccines—The role of the World Health Organisation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040406

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20040629

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20040728

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080806

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080806

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090806

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090806

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100806

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110806

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110806

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120806

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130806

Year of fee payment: 9

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term